论文部分内容阅读
目的:评估血清乙型肝炎大蛋白(HBV-LP)在慢性乙型肝炎(CHB)患者抗病毒疗效评估中的临床价值。方法:120例CHB患者经恩替卡韦治疗96周。分别于用药0、12、24、36、48、72和96周检测HBV-LP和HBV DNA。结果:CHB患者中治疗前HBV-LP与HBV DNA阳性率差异无统计学意义(P>0.05),在抗病毒治疗中,HBV-LP与HBV DNA降低呈一致趋势(P<0.01),HBV-LP含量与HBV DNA拷贝数呈明显正相关关系(P<0.01)。结论:血清HBV-LP检测为抗病毒疗效评估提供有效参考指标。
Objective: To evaluate the clinical value of serum hepatitis B big protein (HBV-LP) in evaluating antiviral efficacy in patients with chronic hepatitis B (CHB). Methods: 120 CHB patients were treated with entecavir for 96 weeks. HBV-LP and HBV DNA were detected at 0, 12, 24, 36, 48, 72 and 96 weeks after treatment. Results: There was no significant difference in the positive rates of HBV-LP and HBV DNA before treatment in patients with CHB (P> 0.05). HBV-LP and HBV DNA showed a consistent trend in anti-viral treatment (P <0.01) LP content and HBV DNA copy number showed a significant positive correlation (P <0.01). Conclusion: Serum HBV-LP test provides an effective reference for the evaluation of anti-virus efficacy.